Barclays »

Aeglea Biotherapeutics shares owned by Barclays

Quarter-by-quarter ownership of Aeglea Biotherapeutics (SYRE) shares owned by Barclays from 13F filings

Historical chart of Barclays investment in Aeglea Biotherapeutics

Tip: Access up to 7 years of quarterly data

All positions including Aeglea Biotherapeutics held by Barclays consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Aeglea Biotherapeutics by Barclays

Quarter filed Position value Share count Share price at filing
2023-12-31 $979k 46k 21.52

More positions owned by Barclays

Invesco Qqq Tr Opt Call Option (QQQ)
SPDR S&ampP 500 ETF TR Opt Put Option (SPY)
Microsoft Corp Opt Call Option (MSFT)
Ishares Tr Opt Call Option (IWM)
Apple (AAPL)
Amazon Opt Call Option (AMZN)
Alphabet Opt Put Option (GOOGL)
NVIDIA Corporation (NVDA)
Tesla Opt Put Option (TSLA)
Meta Platforms Opt Put Option (META)
Ishares Tr Fund (HYG)
Alphabet Opt Call Option (GOOG)
Visa Opt Put Option (V)
Broadcom (AVGO)
Berkshire Hathaway (BRK.B)

View all positions for Barclays

Top funds holding Aeglea Biotherapeutics

Perceptive Advisors
VR Adviser
Commodore Capital
venBio Select Advisor
Cormorant Asset Management
EcoR1 Capital
Franklin Resources
BVF
Wellington Management Company
Citadel Advisors
BlackRock
Braidwell
Global Endowment Management
Vanguard Group
First Turn Management

View all funds holding Aeglea Biotherapeutics